Cargando…

The Role of SGLT2 Inhibitors in Vascular Aging

Vascular aging is defined as organic and functional changes in blood vessels, in which decline in autophagy levels, DNA damage, MicroRNA (miRNA), oxidative stress, sirtuin, and apoptosis signal-regulated kinase 1 (ASK1) are integral thereto. With regard to vascular morphology, the increase in arteri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Le, Ni, Yu-Qing, Zhan, Jun-Kun, Liu, You-Shuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JKL International LLC 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279525/ https://www.ncbi.nlm.nih.gov/pubmed/34341711 http://dx.doi.org/10.14336/AD.2020.1229

Ejemplares similares

Roles and Functions of Exosomal Non-coding RNAs in Vascular Aging
por: Ni, Yu-Qing, et al.
Publicado: (2020)

Function, Role, and Clinical Application of MicroRNAs in Vascular Aging
por: Lin, Xiao, et al.
Publicado: (2016)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
por: Llorens-Cebrià, Carmen, et al.
Publicado: (2022)

New Insights into the Roles and Mechanisms of Spermidine in Aging and Age-Related Diseases
por: Ni, Yu-Qing, et al.
Publicado: (2021)

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
por: Sha, Wenjun, et al.
Publicado: (2020)

Neuroprotective Effect of SGLT2 Inhibitors
por: Pawlos, Agnieszka, et al.
Publicado: (2021)

SGLT2 Inhibitors and Their Antiarrhythmic Properties
por: Kolesnik, Ewald, et al.
Publicado: (2022)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
por: Liu, Shuangbo, et al.
Publicado: (2019)

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
por: Androutsakos, Theodoros, et al.
Publicado: (2022)

Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors
por: Al Thani, Najlaa A., et al.
Publicado: (2023)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms
por: La Grotta, Rosalba, et al.
Publicado: (2022)

Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
por: Schönberger, Ema, et al.
Publicado: (2023)

Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?
por: Nomiyama, Takashi
Publicado: (2020)

The Effects of SGLT2 Inhibitors on Lipid Metabolism
por: Szekeres, Zsolt, et al.
Publicado: (2021)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

Direct cardiac effects of SGLT2 inhibitors
por: Chen, Sha, et al.
Publicado: (2022)

SGLT2 Inhibitors as Potential Anticancer Agents
por: Basak, Debasish, et al.
Publicado: (2023)

Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
por: Evans, Marc, et al.
Publicado: (2022)

Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
por: Pereira, Maria J., et al.
Publicado: (2019)

SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
por: Garofalo, Carlo, et al.
Publicado: (2019)

Class effects of SGLT2 inhibitors on cardiorenal outcomes
por: Kluger, Aaron Y., et al.
Publicado: (2019)

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
por: Hou, Yi-Chou, et al.
Publicado: (2020)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
por: Salvatore, Teresa, et al.
Publicado: (2022)

SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
por: Chan, Jonathan C. H., et al.
Publicado: (2023)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
por: Frąk, Weronika, et al.
Publicado: (2023)

The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
por: Koutentakis, Michail, et al.
Publicado: (2023)

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
por: Tsai, Kai-Fan, et al.
Publicado: (2021)

Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming
por: Gao, Yue-Ming, et al.
Publicado: (2022)

Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
por: Heath, Rebecca, et al.
Publicado: (2022)

Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
por: Theofilis, Panagiotis, et al.
Publicado: (2023)

SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
por: Saisho, Yoshifumi
Publicado: (2020)

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
por: Scisciola, Lucia, et al.
Publicado: (2023)

Mouse Models with SGLT2 Mutations: Toward Understanding the Role of SGLT2 beyond Glucose Reabsorption
por: Unno, Keiko, et al.
Publicado: (2023)

The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
por: Tsampasian, Vasiliki, et al.
Publicado: (2021)

SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
por: Spatola, Leonardo, et al.
Publicado: (2017)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Impact of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging—What Do We Know So Far? (A Narrative Review)
por: Adam, Cristina Andreea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_16rjc810p7ptfqu5jg57iph459